Governance
Investors
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dodekin
Dekavil
Onco IX
OncoFAP Radio Conjugates
Tripokin
Press Releases & Media
Press Releases
Events
Philogen in the news
Media Library
Work with us
Careers
Partnering
About us
Profile
Management
Board
Scientific Advisory Board
Our Science
Strategy
Enabling Technologies
Product Classes
Pipeline
Pipeline
Nidlegy
TM
Fibromun
Darleukin
Dekavil
Dodekin
Onco IX
OncoFAP Radio Conjugates
Tripokin
Press Releases & Media
Press Releases
Events
Media Library
Philogen in the news
Work with us
Careers
Partnering
Investors
Investor Relations
Shareholding
IPO
Press Releases
Financial Statements
Financial Calendar
Internal Dealing
Buyback
Analyst Coverage
Webinars
IR Contacts
Governance
Board of Directors
Board of Statutory Auditors
Documents & Procedures
Shareholders’ Meetings
Codice etico e Modello 231
Sustainability (ESG)
test
Search for:
Recent Posts
Philogen is pleased to invite you to a new webinar on October 1, 2024, at 15:00 GMT | 16:00 CET.
Sun Pharma e Philogen stipulano un accordo di commercializzazione, licenza e fornitura in esclusiva per la commercializzazione del prodotto innovativo FIBROMUN a livello mondiale.
Sun Pharma and Philogen enter into a global Exclusive Commercialization, License, and Supply Agreement for Commercializing the specialty product FIBROMUN
Philogen to attend the European Association of Nuclear Medicine (EANM) annual meeting on October 19-23, 2024
Il Consiglio di Amministrazione Approva la Relazione Finanziaria Semestrale al 30 giugno 2024 (Price sensitive)
Recent Comments
Recent Comments